1. Home
  2. TLSI vs OPP Comparison

TLSI vs OPP Comparison

Compare TLSI & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.83

Market Cap

227.3M

Sector

Health Care

ML Signal

HOLD

Logo RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

OPP

RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

HOLD

Current Price

$7.90

Market Cap

198.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLSI
OPP
Founded
2010
2010
Country
United States
Employees
N/A
N/A
Industry
Medical Specialities
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
227.3M
198.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TLSI
OPP
Price
$4.83
$7.90
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
116.2K
108.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
14.41%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$55.47
N/A
Revenue Next Year
$40.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.42
$7.26
52 Week High
$7.95
$8.83

Technical Indicators

Market Signals
Indicator
TLSI
OPP
Relative Strength Index (RSI) 38.80 48.61
Support Level $4.38 $7.90
Resistance Level $5.04 $8.00
Average True Range (ATR) 0.29 0.06
MACD 0.03 0.01
Stochastic Oscillator 48.26 45.28

Price Performance

Historical Comparison
TLSI
OPP

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

Share on Social Networks: